Khiron is a company that is promoting medicine, innovation, and efficient science, technology with responsibility and commitment to contribute to Colombia’s economies. The company is present in the medical cannabis business through the line “Kuida”, which is selling products in the United States. Khiron is planning to start investing in medical cannabis to help clinics in Peru.
Khiron, a company that specializes in the production and commercialization of Colombian-Canadian medical cannabis, has focused on cannabis treatments in Peru. They plan to replicate the business model that they’ve already tested and applied in Colombia.
Stay informed with the latest hemp news and don’t waste your time searching the net when you can get the needed information in one application. The Hemp.im application covers topics like cannabis legality, the various health benefits of hemp and more.
Khiron makes plans for Peru
“We are exploring the feasibility of replicating our patient-care model that already exists in Colombia, through a specialized clinic,” said Luis Márquez, the company’s general manager.
He refers to the Latin American Institute of Neurology and Nervous System (ILANS) which Khiron acquired towards the end of 2018. There, he tends to about 100,000 patients per year. These patients suffer from disorders associated with sleep, pain, and other issues.
Since this years first-quarter, Khiron has taken its first steps in the local Peruvian market by looking into cannabis treatments. Additionally, they are approaching the medical community with the goal of ensuring the “safe and effective” access of medical cannabis to patients.”
For these purposes, 500 doctors have been trained in nine specialties. In order to implement its local strategy, the company is waiting for the definition and approval of the final provisions of Law 30681, regulating medicinal and recreational cannabis use.
Potential investment conditions
“We are optimistic about the region’s progress and praise the work done so far. However, we believe that these delays mainly affect patients, who are in the need to mitigate their ailments and could turn to an illegal market,” Luis Márquez explained.
According to Márquez, the company is expecting to start operations for medical cannabis next year.
“We are evaluating the potential investment conditions for Peru throughout different business units,” he said, pointing to the company’s pharmaceuticals, cosmetics, veterinary and research divisions.
Khiron’s headquarters in Colombia’s capital
To supply its different markets in Latin America (Chile, Mexico, and Uruguay) and the world, the company has invested $12 million in a medical cannabis production center in Doima, southwest Bogotá.
The project, which was implemented in 2018, has a total processing capacity of 158,000 kilos of dried cannabis flower per year, of which 25,000 are used today.
The company obtained the license to distribute and export the product, so it is ready to start such activities, reported Marquez.
“By the time the final provisions are fine-tuned for medical cannabis in Peru, the products could be exported here,” he said.
DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Hemp.im, its management, staff or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in El Comercio, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Hemp.im assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Hemp.im is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.